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Radiotherapy has been widely used given its increase in the successful outcomes and cure of 
some cancers. 
Aim: To evaluate the functionality of the auditory system in patients who underwent radiotherapy 
treatment for head and neck tumors. 
Materials and Methods: From May 2007 to May 2008, otorhinolaryngological and audiological 
evaluation (Pure Tone Audiometry (air and bone conduction), Speech Audiometry, Tympanometry, 
Acoustic Reflex testing and Distortion Product Otoacoustic Emissions) were performed in 19 patients 
diagnosed with head and neck neoplasia and treated with radiotherapy. Prospective case series study. 
Results: 10.5% left ears and 26.3% right ears had bilateral hearing loss soon after radiotherapy 
according to ASHA criteria. 
Conclusions: Radiotherapy treatment for head and neck cancer has ototoxic effects. Early programs 
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INTRODUCTION
Hearing loss is one of the main complications of 
head and neck cancer tumors1. Recently, adding che-
motherapy (QT) with cisplatin to radiotherapy (RT) has 
enhanced the survival of patients with such neoplasia, 
thus becoming the standard treatment for locally advanced 
tumors. Nonetheless, all types of treatment, radiotherapy 
and chemotherapy with cisplatin, are known for their 
ototoxic effects.
Irreversible hearing loss, as a consequence of head 
and neck radiotherapy has been studied and the literature 
shows a great variability in the incidence of ototoxicity, 
varying between 18% and 50%.2-5
Insofar as the ototoxic effects caused by radiation 
to the head and neck are concerned, the literature is full 
of controversies.
Smouha and Karmody reported external auditory 
meatus necrosis, osteoradionecrosis of the temporal bone, 
otitis media, conductive hearing loss, otalgia and tinnitus 
as main consequences.6
Bohne et al.7 reported that the degeneration of hair 
cells, both sensorial and support cells may happen up to 
two years after the end of radiotherapy. Other authors 
have reported a bilateral sensorineural deficiency in the 
high frequencies as a consequence to the radiation.8-10
Our study aimed at assessing the auditory system 
function in patients submitted to radiotherapy in the head 
and neck region because of the concern with its ototoxic 
effects.
MATERIALS AND METHODS
Prospective study carried out at the Department 
of Otorhinolaryngology and Oncology/Radiotherapy, 
approved by the Ethics in Research Committee, under 
protocol # 165/06.
We had a total of 19 male patients diagnosed with 
head and neck neoplasia enrolled in this study.
Because of primary tumor characteristics and clinical 
staging, all the patients were treated with radiotherapy.
After confirming the diagnosis of neoplasia throu-
gh a pathology exam and indication of radiotherapy as 
treatment, the patients were referred to the ENT ward for 
otolaryngological and audiological evaluation, made up in 
two stages: before and after radiotherapy. The following 
procedures were held: Clinical-ENT anamneses and evalua-
tion, speech and hearing therapy interview, air conduction 
and bone tonal threshold audiometry, logoaudiometry, 
immittance evaluation, stapes reflex study and distortion 
product evoked otoacoustic emissions (DP-EOAE).
Previous chemo and/or radiotherapy treatment, 
whether concurrent or not was considered as an exclusion 
factor, as well as patients with rhinopharynx neoplasia.
We took off the sample two patients with this type 
of neoplasia because of the presence of unilateral pretreat-
ment conductive hearing loss (neoplasia side) and normal 
post-treatment hearing (probably due to a reduction in 
tumor size and Eustachian tube decompression).
In the radiotherapy program, all the patients were 
staged by means of a complete physical exam, direct or 
indirect laryngoscopy, head and neck CT scan and chest 
x-ray before treatment.
The dose of radiotherapy prescribed varied ac-
cording to the disease’s primary site and primary tumor 
staging. Before starting the radiotherapy sessions, the pa-
tients were submitted to conventional simulation (x-Ray), 
in order to outline the radiotherapy field and make up of 
moldable thermoplastic masks used for immobilization 
in the supine position and to outline the treatment area.
Treatment limits (radiation field) vary according to 
the disease’s primary site. Nonetheless, because of the 
advanced nature of the cases, all the patients had the 
upper border of the radiotherapy field on the skull base, 
which resulted in the inclusion of the cochlea in the ra-
diotherapy field.
In order to calculate the radiotherapy treatment 
volume (RTV) we used the patient’s side-to-side distance, 
measured during the process of simulation and multiplied 
by the resulting area of simulation in each patient.
Statistical analysis
In order to analyze the differences between the 
tonal threshold mean values for the different frequencies 
before and after treatment, we did the t-student test.
In order to check and see which mean values (above 
or below) for age, volume and RT dose variables would 
have some association with the reduction of the tonal 
thresholds after treatment we employed the Fisher’s Exact 
test; and according to the contingency table we calculated 
the Odds Ratio in order to establish the relationship betwe-
en the likelihood of occurrence and non-occurrence of a 
post-treatment auditory change, considering the variables: 
age, volume and RT dose.
As a reduction of hearing acuity we considered the 
ASHA criteria which considers a 20dB increase in ototoxi-
city effect in one isolate frequency or of 10 dB in two or 
more successive frequencies.11
For all the statistical tests, we considered the value 
up to 5% for significance level (p < 0.05).
RESULTS
The patients’ characteristics, including gender, age, 
tumor anatomical location, distribution by clinical staging, 
radiotherapy dose by fraction, total dose of radiotherapy 
and radiotherapy treatment volume are described on 
Chart 1.
As seen on Chart 1, all the patients in this group 
were males in the age range between 37 and 82 years, 
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and the mean age was 63.6 years and median of 64 years. 
The total radiotherapy dose varied between 60.0 Gy and 
72.0 Gy - mean dose of 65.6 Gy and median dose of 64 
Gy, with daily dose variation between 1.8Gy -2,0 Gy. As 
to radiotherapy mean treatment volume we found 1,743.8 
cm3, median of 1,664 cm3 and a variation of 768 cm3 to 
2,828 cm3.
Among the 19 patients and 38 ears evaluated we 
noticed through the ENT evaluation that one ear had per-
forated tympanic membrane and 37 tympanic membranes 
were intact. During the radiotherapy sessions, only one ear 
showed otoscopic changes, and this membrane was intact 
before treatment and it was retracted after it. In the first 
audiologic evaluation this ear had sensorineural auditory 
loss and after treatment the loss was mixed.
As to the audiological evaluations performed before 
the radiotherapy treatment we noticed in our sample that 
only 4 ears had thresholds within the normal ranges (lower 
than 20 dB in all the frequencies) and most of the assessed 
patients already had some type of hearing disorder. One 
ear had moderate mixed hearing loss.
The remaining ears had sensorineural changes: 
moderate hearing loss (8 ears); mild hearing loss (5 ears), 
hearing loss starting at 2KHz (2 ears), starting at 3KHz (8 
ears ), starting at 4KHz (7 ears) and starting at 6KHz (3 
ears).
By analyzing the data we can see that the mean 
values of the frequencies assessed between 250Hz and 
8 KHz were changed when pre and post radiotherapy 
treatments were compared, as shown on Chart 2, which 
also shows data concerning standard deviation, confidence 
interval and p-value for each frequency bilaterally.
According to ASHA criteria, 10.5% left ears and 
26.3% right ears had reduction in their tonal auditory 
thresholds immediately after the end of the radiotherapy. 
Post-treatment audiological evaluations were carried out 
within 15 days after the last radiotherapy session.
Age, radiotherapy treatment value and total radia-
tion dose according to Fisher’s exact test analyses did not 
show relationship with a reduction on the post-treatment 
tonal auditory thresholds when ASHA criteria were con-
sidered (Chart 3).
DISCUSSION
Radiotherapy is one of the effective treatment mo-
dalities for head and neck tumors.
For initial T1 and T2 lesions the results for RT alone 
are comparable to those obtained from surgical treatment. 
For more advanced lesions, such as some head and neck 
anatomical sites, RT associated with QT has been prefer-
red because of the possibility of preserving the organ. 
Radiotherapy complications happen in specific sites, in 
other words, they depend on the area (radiotherapy field) 
Chart 1. Distribution of the individual characteristics of each patient from Group 1 (n = 19).
Gender Age Anatomical Location Staging Fractioned dose Total dose Treatment volume
1 M 66 Parotid T4N0M0 2,0 60,0 768
2 M 64 Larynx T4N0M0 1,8 70,2 1.261
3 M 73 Oropharynx T4N3M0 1,8 70,2 2.828
4 M 62 Larynx T3N0M0 2,0 72,0 1.562
5 M 66 Parotid T1N1M0 2,0 60,0 1.411
6 M 59 Oropharynx T2N3M0 1,8 72,0 2.608
7 M 52 Larynx T2N0M0 2,0 66,0 1.664
8 M 45 Oropharynx T3N0M0 2,0 60,0 992
9 M 52 Oropharynx T4N0M0 1,8 -2,0 61,0 1.930
10 M 64 Oropharynx T2N1M0 1,8 61,2 1875
11 M 66 Larynx T4N2M0 2,0 72,0 2.044
12 M 77 Larynx T2N0M0 1,8 66,6 1.822
13 M 74 Larynx T4N3M0 1,8 72,0 1.980
14 M 58 Oropharynx T2N0M0 2,0 60,0 1.605
15 M 78 Larynx T4N0M0 2,0 64,0 1.060
16 M 58 Larynx T4N0M0 1,8 60,0 1.597
17 M 76 Hypopharynx T2N0M0 1,8 -2,0 72,0 2.400
18 M 82 Oropharynx T2N1M0 2,0 62,0 1.905
19 M 37 Larynx T2N0M0 1,8 66,6 1.822
530
Brazilian Journal of otorhinolaryngology 76 (4) July/august 2010
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
Chart 2. Distribution of the tonal auditory thresholds and the difference among them before and after treatment, confidence interval and p-









 250 Hz 21,57 23,15 1,58 -6,12 2,96 0,47
 500 Hz 19,47 22,10 2,63 -7,47 2,21 0,26
 1 KHz 21,84 23,68 1,84 -6,40 2,71 0,40
RE 2 KHz 27,89 31,31 3,42 -8,44 1,59 0,16
 3 KHz 37,11 42,36 5,25 -12,00 1,48 0,18
 4 KHz 45,00 52,89 7,89 -15,31 -0,47 0,38
 6 KHz 62,10 55,00 -7,10 -0,27 14,48 0,58
 8 KHz 62,89 55,79 -7,10 0,13 14,07 0,04
 250 Hz 21,84 21,57 -0,27 -2,57 3,10 0,84
 500 Hz 17,63 17,89 0,26 -2,86 2,33 0,83
 1 KHz 18,68 20,78 2,10 -4,27 0,06 0,05
LE 2 KHz 26,05 27,63 1,58 -3,85 0,70 0,16
 3 KHz 36,57 34,47 -2,10 -0,82 5,03 0,14
 4 KHz 45,26 43,68 -1,58 -1,32 4,48 0,26
 6 KHz 53,15 51,31 -1,84 -2,02 5,71 0,33
 8 KHz 55,00 62,89 7,89 -14,18 -1,60 0,01
Chart 3. Data from the relationship between the likelihood of occurrence and non-occurrence of post-radiotherapy hearing loss, taking into 
account the variables: age, total dose of radiation and volume of radiotherapy treatment volume with ASHA criteria. 
   Age Total p-value
   ≤ 64 years > 64 years   
Hearing loss Yes 8 7 15 0,667
ASHA No 2 2 4  
Total  10 9 19
   RT total dose Total p-value
   ≤ 64 Gy > 64 Gy   
Hearing loss Yes 1 2 3 0,41
ASHA No 8 16 24  
Total  9 18 27
   RT Treatment volume Total p-value
   ≤ 1800 cm > 1800 cm   
Hearing loss Yes 1 3 4 0,333
ASHA No 8 7 15  
Total  9 10 19
where the radiation is being deployed.12
Especially for advanced disease, because of the 
presence of large tumors, there is the need to irradiate 
the primary site of the disease and those areas suspected 
of microscopic disease, having potential side effects as 
consequences, especially on the healthy tissue near the 
tumor site. As an example of this we have ototoxicity in the 
cases of head and neck RT, especially when the cochlea 
is inside the radiation field.
Although we do not do 3-D image shaped RT, we 
were able to estimate the RTV for each patient using the 
technical parameters for simulation and treatment. In a 
statistical analysis we compared the group of patients 
who received RTV in greater or lower than 1,800 cm3, and 
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no significant auditory changes were seen among them. 
Therefore, for the sample investigated, the radiotherapy 
treatment volume was not considered an important risk 
factor for ototoxicity (Chart 3).
As to the radiation dose factor, Che et al. reported 
a relationship between ototoxicity and the punctual dose 
of radiation received by the cochlea. When using the 3-D 
shaped RT, there was a significant increase in the risk of 
acquiring hearing loss in patients who received radiation 
doses starting from 48 Gy.13
According to results from our statistical analyses, 
we did not observe significant association regarding to-
nal auditory thresholds after treatment for patients who 
received radiation doses higher than 64 Gy. It is worth 
stressing that this is the total radiation dose administered 
to the treatment field and not the dose received by the 
cochlea (Chart 3).
The increase in the age of the patients submitted 
to treatment has also been shown as a factor involved in 
the increase of risk for hearing reduction. Some studies 
associate age increase with the increase in ototoxicity.14,15
In our sample, all the patients assessed had ages 
≥ 40 years, and the mean age of 64 years. In a statistical 
analysis we also did not notice statistically significant di-
fferences between the groups of patients with ages above 
and below 64 years (Chart 3).
As to changes in tonal auditory thresholds immedia-
tely after radiotherapy, we find in our sample an increase 
in tonal thresholds for the frequencies of 4 KHz in the 
right ear and  8 KHz in the left ear.
All the patients in our sample had hearing disorders; 
36.8% of them had significant changes according to ASHA 
ototoxicity criteria and 63.2% had threshold increases 
which did not fit these criteria.
In a prospective study, Ho et al. assessed 526 
ears from patients with nasopharynx cancer treated by 
radiotherapy alone.16 With a follow up of 4.5 years they 
observed that the hearing changes started immediately 
after the end of the radiotherapy. After two years, 40% of 
the patients partially recovered from their hearing change, 
while the remaining of the patients had a worsening as 
the years passed.
We stress that nasopharyngeal neoplasias may 
cause conductive hearing loss because of Eustachian tube 
compression.
In regards of the auditory complaints presented by 
the patients, some studies report tinnitus, while others 
report that tinnitus is usually transitional, disappearing 
within hours or weeks after the treatment and it happens 
to 2% to 36% of the patients.17-19. In our sample, only one 
patient complained of tinnitus during and after radiothe-
rapy. Three patients already complained of tinnitus before 
the treatment and did not show changes during treatment. 
One patient complained of post-treatment otalgia.
CONCLUSION
Patients with head and neck cancer submitted to 
conventional radiotherapy have a high incidence of tonal 
hearing threshold increases at the end of treatment.
Our data stress the importance of doing a pre and 
post treatment audiologic evaluation in all the patients 
submitted to conventional radiotherapy to treat head and 
neck tumors.
Thus, we stress the importance of these instruc-
tions on the consequences of radiotherapy, so that the 
patients can be included early on in hearing rehabilitation 
programs.
FINAL REMARKS
All the patients with hearing reduction and who 
reported hearing problems were instructed regarding the 
use of hearing aids.
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